NCT06909825View on ClinicalTrials.gov

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

January 29, 2030

Study Completion Date

August 12, 2030

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

FPI-2265

PSMA ligand radiolabeled with Ac225

DRUG

Olaparib

Poly (ADP-ribose) polymerase (PARP) inhibitor

Trial Locations (4)

2113

Macquarie University Hospital, Macquarie Park

3000

Peter MacCallum Cancer Center, Melbourne

4102

Princess Alexandra Hospital, Woolloongabba

5037

Icon Cancer Centre Kurralta Park, Kurralta Park

Sponsors
All Listed Sponsors
lead

Fusion Pharmaceuticals Inc.

INDUSTRY